{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T03:51:42Z","timestamp":1774497102622,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T00:00:00Z","timestamp":1179964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2007,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background and Aim:\u2002<\/jats:bold> The 5\u2010HT<jats:sub>4<\/jats:sub> receptor agonist tegaserod (6\u2003mg b.i.d.) provides significantly better overall multiple symptom relief compared with placebo in patients with irritable bowel syndrome with constipation (IBS\u2010C). The clinical benefit and safety of tegaserod in IBS\u2010C patients has been demonstrated worldwide in several studies. The aim of this study was to obtain further safety and tolerability data in patients with IBS in the Asia\u2013Pacific region, and to assess patients' satisfaction and compliance with treatment and willingness to re\u2010use tegaserod in a post\u2010marketing setting.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> A multicenter, single\u2010arm, open\u2010label trial was conducted at 869 outpatient centers in 10 countries. Men and women with IBS, whose predominant bowel symptom was not diarrhea (non\u2010D\u2010IBS), received tegaserod for 4\u201312\u2003weeks. Safety and tolerability were assessed by recording adverse events (AE). Patients were questioned about compliance, satisfaction with treatment and willingness to use tegaserod in future.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Data were available from 14\u2003537 patients (18% men, 82% women). Four percent of patients reported at least one AE. The most common AE were diarrhea (2%) and abdominal pain (1%), and most treatment\u2010related AE occurred in the first week of treatment. Serious AE (SAE) were observed in eight patients, and no deaths were reported. Most patients (79%) reported to be satisfied or very satisfied with treatment, and 76% stated they would use tegaserod in the future. Compliance was 97%.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Tegaserod has a favorable safety and tolerability profile for treating non\u2010D\u2010IBS and IBS\u2010C in men and women in the Asia\u2013Pacific region. Satisfaction with tegaserod treatment can be expected in the majority of patients.<\/jats:p>","DOI":"10.1111\/j.1440-1746.2007.04955.x","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T11:21:52Z","timestamp":1180092112000},"page":"1190-1198","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety, tolerability and satisfaction with tegaserod therapy in Asia\u2013Pacific patients with irritable bowel syndrome with constipation"],"prefix":"10.1111","volume":"22","author":[{"given":"Kwong M","family":"Fock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Asia Pacific Gastroenterology Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2005.00627.x"},{"key":"e_1_2_6_3_2","volume-title":"Rome II. The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment; a Multinational Consensus.","author":"Drossman DA","year":"2000"},{"key":"e_1_2_6_4_2","first-page":"35","article-title":"Epidemiologic study of the irritable bowel syndrome in Beijing: stratified randomized study by cluster sampling","volume":"113","author":"Pan G","year":"2000","journal-title":"Chin. Med. J. (Engl.)"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01939.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2002.02871.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.04161.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01711.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-003-0035-5"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0889-8553(21)00551-3","article-title":"Motility disorders in the irritable bowel syndrome","volume":"20","author":"Lind CD","year":"1991","journal-title":"Gastroenterol. Clin. North Am."},{"issue":"2","key":"e_1_2_6_11_2","first-page":"S252","article-title":"The role of serotonin in the pathophysiology of irritable bowel syndrome","volume":"7","author":"Crowell MD","year":"2001","journal-title":"Am. J. Manage. Care"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v10.i12.1830"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01449.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v10.i19.2836"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705929"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200504000-00005"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01094.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01372.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.070789"},{"key":"e_1_2_6_20_2","first-page":"CD003960","article-title":"Tegaserod for the treatment of irritable bowel syndrome","volume":"1","author":"Evans BW","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(01)80106-2"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.5.671"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6138.653"},{"key":"e_1_2_6_24_2","volume-title":"Rome. The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment: a Multinational Consensus.","author":"Drossman DA","year":"1994"},{"key":"e_1_2_6_25_2","first-page":"88","article-title":"[A randomized, double\u2010blind, placebo\u2010controlled, multicenters study to assess the efficacy and safety of tegaserod in Chinese patients with constipation\u2013predominant irritable bowel syndrome]","volume":"42","author":"Lin SR","year":"2003","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"e_1_2_6_26_2","first-page":"21","article-title":"Efficacy and tolerability of tegaserod in constipation dominant Irritable Bowel Syndrome","volume":"14","author":"Shah SH","year":"2004","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(02)05326-1"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02294.x"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.2007.04955.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.2007.04955.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T16:18:29Z","timestamp":1697386709000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.2007.04955.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["10.1111\/j.1440-1746.2007.04955.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.2007.04955.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8]]},"assertion":[{"value":"2007-08-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}